LONDON (Alliance News) - Hikma Pharmaceuticals PLC on Monday said its US unit has launched Clobazam oral suspension and Clobazam tablets, the generic equivalent to Onfi.
Clobazam is the non-brand name of the brand-name drug commonly known as Onfi in the US. Onfi is a registered trademark of Danish pharmaceutical firm Lundbeck Inc.
Hikma's Clobazam is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or older.
According to the American healthcare consultant company IQVIA, US sales of Clobazam oral suspension were USD260 million and of Clobazam tablets were USD601 million in the 12 months to the end of September.
"We are very excited to add Clobazam oral suspension and Clobazam tablets to our product portfolio," said Generics Division President Brian Hoffmann.
"This will be among the first generics available on the market and we are pleased to improve patients' access to this important medicine," Hoffmann added.
Hikma Pharmaceuticals shares were trading 0.7% lower on Monday at 1,692.50 pence each.
Hikma Pharmaceuticals (HIK)